Zymeworks (ZYME)
NASDAQ:ZYME
ZYME Stock Chart & Stats
$25.94
-$0.11(-0.77%)
At close: 4:00 PM EST
$25.94
-$0.11(-0.77%)
Day’s Range― - ―
52-Week Range$9.03 - $28.49
Previous CloseN/A
Volume35.38K
Average Volume (3M)697.00K
Market Cap
$1.93B
Enterprise Value$1.89B
Total Cash (Recent Filing)$228.80M
Total Debt (Recent Filing)$18.27M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 06, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding73,749,600
10 Day Avg. Volume541,048
30 Day Avg. Volume697,001
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.39
Price to Sales (P/S)18.72
P/FCF Ratio-57.45
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue17.87
Enterprise Value/Gross Profit18.16
Enterprise Value/Ebitda-21.21
Forecast
1Y Price Target
$39.75Price Target Upside53.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.13
Revenue Forecast (FY)$294.64M
Bulls Say, Bears Say
Bulls Say
Balance Sheet Flexibility Via Royalty FinancingA royalty‑backed financing arrangement and large royalty receipts increase available cash, enabling low‑cost, non‑dilutive funding that can support share repurchases, business development, and continued pipeline investment.
Clinical And Regulatory Momentum For Lead HER2 AssetBreakthrough Therapy Designation combined with Phase 3 results showing improved progression‑free and overall survival positions the HER2 antibody as a potential new standard in gastric and gastroesophageal cancer, substantially enlarging commercial opportunity if approved.
Regulatory Designation For Investigational ADCFDA Fast Track Designation for the folate receptor alpha‑targeting ADC validates early safety and efficacy signals and could accelerate dose‑escalation data and regulatory engagement for the program.
Bears Say
Competitive Pressure In FRa ADC FieldA competing folate receptor alpha ADC that already holds Breakthrough Therapy Designation raises the bar for differentiation and could erode market share and pricing power for similar candidates.
Funding And Execution RiskPersistent operating losses, high cash burn, and a limited cash runway increase the risk of additional dilutive financing or heavy reliance on milestone payments, which could pressure execution if anticipated payments are delayed.
Safety And Tolerability RisksReports of meaningful rates of serious treatment‑related adverse events and chemotherapy discontinuations highlight tolerability concerns that could limit clinical uptake and complicate regulatory assessments.
Zymeworks News
ZYME FAQ
What was Zymeworks’s price range in the past 12 months?
Zymeworks lowest stock price was $9.03 and its highest was $28.49 in the past 12 months.
What is Zymeworks’s market cap?
Zymeworks’s market cap is $1.93B.
When is Zymeworks’s upcoming earnings report date?
Zymeworks’s upcoming earnings report date is May 06, 2026 which is in 33 days.
How were Zymeworks’s earnings last quarter?
Zymeworks released its earnings results on Mar 02, 2026. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.461 by -$0.089.
Is Zymeworks overvalued?
According to Wall Street analysts Zymeworks’s price is currently Undervalued.
Does Zymeworks pay dividends?
Zymeworks does not currently pay dividends.
What is Zymeworks’s EPS estimate?
Zymeworks’s EPS estimate is -0.3.
How many shares outstanding does Zymeworks have?
Zymeworks has 73,749,600 shares outstanding.
What happened to Zymeworks’s price movement after its last earnings report?
Zymeworks reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.461. Following the earnings report the stock price went up 0.086%.
Which hedge fund is a major shareholder of Zymeworks?
Currently, no hedge funds are holding shares in ZYME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.75 (53.24% Upside)
$39.75 (53.24% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 505.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
123.23%
12-Months-Change
Fundamentals
Return on Equity
-26.00%
Trailing 12-Months
Asset Growth
-25.17%
Trailing 12-Months
Company Description
Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
ZYME Company Deck
ZYME Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive clinical and commercial momentum centered on zanidatumab — a Phase III survival result (median PFS >1 year, median OS >2 years), regulatory progress, material near- and longer-term milestone and royalty economics, a $250M nondilutive financing structured to preserve long-term upside, and meaningful revenue growth (~39% y/y) with an improved net loss (≈34% reduction). Management reiterated cost discipline (targeting ~20% lower adjusted operating expense in 2026) and pipeline progress (ZW251 enrolling, INDs on track for 2026). Key risks include reliance on contingent milestone payments for runway, a ~16.5% decline in cash year-over-year, some near-term encumbrance of 30% of zanidatumab royalties to service the note, and remaining clinical/regulatory uncertainties (e.g., next OS interim and multi-year timelines for breast cancer readouts). On balance, the positive clinical validation, revenue/milestone upside, and strategically structured nondilutive financing materially outweigh the risks presented.View all ZYME earnings summariesZYME Stock 12 Month Forecast
Average Price Target
$39.75
▲(53.24% Upside)
Technical Analysis
Arcus Biosciences
―
Replimune Group
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
Currently, No data available
---